Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and Webcast

On January 26, 2026, Beyond Air, Inc. (NASDAQ: XAIR) announced its plans to report its financial results for the third fiscal quarter, which ended on December 31, 2025. The disclosure will take place on February 13, 2026, followed by a conference call and webcast at 8:00 AM Eastern Time. Interested parties can join the call by dialing domestic number 1-877-407-0784 or international number 1-201-689-8560, using the conference ID 13758405. A live webcast will also be available on the company’s website, and an online replay will be accessible shortly after the call concludes.

Beyond Air, a commercial-stage medical device and biopharmaceutical company, focuses on utilizing nitric oxide (NO) to enhance the quality of life for patients with respiratory conditions, neurological disorders, and solid tumors. The company has achieved significant regulatory milestones, including FDA approval and CE Mark for its initial product, LungFit PH, designed for treating hypoxic respiratory failure in term and near-term neonates.

In addition to LungFit PH, Beyond Air is advancing several other innovative LungFit systems currently undergoing clinical trials. These trials target severe lung infections, including viral community-acquired pneumonia and non-tuberculous mycobacteria (NTM). Furthermore, Beyond Cancer, Ltd., an affiliate of Beyond Air, is exploring the potential of ultra-high concentrations of NO, implemented through a proprietary delivery system, for the treatment of certain solid tumors in pre-clinical investigations.

For those seeking further information about Beyond Air's ongoing projects and conference call details, additional resources can be found on their website, www.beyondair.net.

As Beyond Air, Inc. (NASDAQ: XAIR) prepares to report its third fiscal quarter 2026 financial results on February 13, 2026, investors should closely consider a few critical factors that may influence the company's market performance post-announcement.

First, Beyond Air's focus on harnessing nitric oxide (NO) for various medical applications positions the company uniquely within the medical device and biopharmaceutical sectors. The recent FDA approval for its LungFit PH system underscores regulatory confidence in Beyond Air's technology, which could stimulate investor interest. Attention should be directed towards management's commentary regarding the sales pipeline and adoption rates of LungFit PH, as well as updates on ongoing clinical trials for its other LungFit systems.

Second, investors should be mindful of how Beyond Air plans to navigate competition and market expansion. The conference call will likely address the company's strategies for scaling production and distribution, especially as it broadens its focus not only on respiratory illnesses but also on neurological disorders and solid tumors.

Lastly, careful analysis of the financial metrics disclosed during the earnings call—such as revenue growth, R&D expenditures, and cash burn rate—will provide insight into Beyond Air’s operational efficiency and financial health.

In anticipation of the earnings report, it may be prudent for investors to consider establishing or adjusting positions based on the management's forward-looking guidance and the market's perception of the company’s innovation pipeline. Overall, Beyond Air presents a compelling growth opportunity, but potential volatility surrounding earnings announcements necessitates a cautious approach. Investors should align their strategies with a clear understanding of the risk-reward landscape that Beyond Air navigates in the highly competitive biotech arena.